The go-to-market strategies deployed by emerging biotechs to launch their first products into Europe have changed in the last two years.

Instead of building their own infrastructure, emerging biotechs are primarily commercialising their products through out-licencing, partnerships or global biopharma buy-outs.

To hear more about the findings, please read the latest report by the Deloitte Life Sciences Catalyst team.

https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/life-scienc…